Tyra Biosciences, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Tyra Biosciences (market cap ~$297M) reported Q2 2026 results with cash of $353.9M providing runway into H2 2028. Key milestones: SURF302 Phase 2 bladder cancer study (n>40 enrolled) initial data due September 2026; BEACH301 achondroplasia trial advancing to 5th dose level with ~25 children, results expected end Q1 2027; SURF303 LG-UTUC study results expected 2027. Company appointed Jonathan Day as EVP Clinical Development and amended ATM agreement to raise up to $250M additional capital. Q2 R&D expenses increased 61% YoY to $39.2M; net loss widened to $45.6M from $28.1M YoY.
Why this rating
Routine clinical-stage biotech disclosure. Cash sufficient; meaningful pipeline progress but early-stage Phase 2 data. Capital raise flexibility positive, but no transformational event relative to $297M market cap.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.